Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Analysts at William Blair upped their FY2024 earnings estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($2.65) for the year, up from their prior estimate of ($2.73). William Blair has a "Outperform" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.60) per share. William Blair also issued estimates for Alto Neuroscience's Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($3.06) EPS.
A number of other analysts also recently issued reports on the stock. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. Wedbush cut Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Stifel Nicolaus decreased their price objective on Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Finally, Rodman & Renshaw downgraded shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and an average price target of $20.00.
View Our Latest Stock Report on ANRO
Alto Neuroscience Trading Up 2.0 %
ANRO traded up $0.09 during trading on Monday, reaching $4.61. 327,572 shares of the company traded hands, compared to its average volume of 374,663. The company has a current ratio of 13.10, a quick ratio of 19.85 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 12-month low of $3.61 and a 12-month high of $24.00. The firm has a fifty day simple moving average of $9.69 and a 200 day simple moving average of $11.27.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05.
Hedge Funds Weigh In On Alto Neuroscience
A number of large investors have recently made changes to their positions in the company. Federated Hermes Inc. boosted its position in shares of Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $128,000 after buying an additional 3,000 shares during the period. BNP Paribas Financial Markets boosted its holdings in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company's stock valued at $49,000 after acquiring an additional 3,715 shares during the period. Philadelphia Financial Management of San Francisco LLC grew its position in Alto Neuroscience by 1.5% in the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company's stock valued at $5,147,000 after acquiring an additional 6,663 shares during the last quarter. Rhumbline Advisers purchased a new stake in Alto Neuroscience in the second quarter worth $113,000. Finally, Jane Street Group LLC bought a new stake in shares of Alto Neuroscience during the third quarter worth $124,000.
Alto Neuroscience Company Profile
(
Get Free Report)
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Further Reading
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
